<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772576</url>
  </required_header>
  <id_info>
    <org_study_id>BSC-CDM00052753</org_study_id>
    <secondary_id>C1830</secondary_id>
    <nct_id>NCT01772576</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the Reliance 4-Front Lead</brief_title>
  <official_title>RELIANCE 4-FRONT™ Active Fixation Defibrillation Lead Post Market Clinical Follow-Up (PMCF) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to gather data to establish the chronic safety, performance
      and effectiveness of the RELIANCE 4-FRONT™ Active Fixation Defibrillation Leads.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RELIANCE 4-FRONT Defibrillation Lead Post Market Clinical Follow-Up Study is a
      prospective, non-randomized, multi-center, single-group, post market clinical study to
      establish the chronic safety, performance and effectiveness of the RELIANCE 4-FRONT active
      fixation defibrillation leads.

      A total of 167 patients (including 10 % attrition) are required to evaluate the Primary
      Endpoint.

      Up to 20 Investigational centers located in Europe and Asia Pacific. Lead-related
      Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.

      Lead-related complications associated with the RELIANCE 4-FRONT active fixation lead will
      count toward this endpoint.

      Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant.

      Lead-related complications associated with the RELIANCE 4-FRONT active fixation lead will
      count toward this endpoint.

        -  Lead-related Complication-Free Rate from 3 Months through 24 Months Post-Implant

        -  Pacing Threshold at 0.5 ms pulse width at 3 Months Post-Implant

        -  Sensed Amplitude at 3 Months Post-Implant

        -  Pacing Impedance at 3 Months Post-Implant All endpoints will be assessed for the
           RELIANCE 4-FRONT active fixation lead.

      Clinic visits will occur at:

        -  Enrollment Visit (no later than 30 days prior to implant procedure)

        -  Implant Procedure (Day 0; all future follow ups based on this date)

        -  Pre-Discharge Clinic Visit (3 - 72 hours post-implant)

        -  One Month Clinic Visit (30±7 days)

        -  3 Month Clinic Visit (91 ± 21 days)

        -  6 Month Clinic Visit (180 ± 30 days)

        -  12 Month Clinic Visit (365 ± 45 days)

        -  18 Month Clinic Visit (545± 45 days)

        -  24 Month Clinic Visit (730 ± 45 days) The study will be considered completed after all
           subjects have completed the 24 Month follow-up and study completion is anticipated in
           2015. Primary endpoint completion is anticipated after all subjects have completed the 3
           Month follow-up visit. All study required visits will be completed during clinic visits.

      Hypotheses testing in the RELIANCE 4-FRONT PMCF Study will use standard statistical
      methodology as specified more in detail in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication Free Rate</measure>
    <time_frame>3-months follow-up</time_frame>
    <description>Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication Free Rate</measure>
    <time_frame>3 months through 15 months post implant</time_frame>
    <description>Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complication Free Rate</measure>
    <time_frame>3 Months through 24 Months Post-Implant</time_frame>
    <description>Lead-related Complication-Free Rate from 3 Months through 24 Months Post-Implant</description>
  </other_outcome>
  <other_outcome>
    <measure>Pacing Threshold</measure>
    <time_frame>3-months post-implant</time_frame>
    <description>Pacing Threshold at 0.5 ms pulse width at 3 Months Post-Implant</description>
  </other_outcome>
  <other_outcome>
    <measure>Sensed Amplitude</measure>
    <time_frame>3 Months Post-Implant</time_frame>
    <description>Sensed Amplitude at 3 Months Post-Implant</description>
  </other_outcome>
  <other_outcome>
    <measure>Pacing Impedance</measure>
    <time_frame>3 Months Post-Implant</time_frame>
    <description>Pacing Impedance at 3 Months Post-Implant</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Tachycardia</condition>
  <arm_group>
    <arm_group_label>Reliance 4-Front</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, all patients will be implanted with the Reliance 4-Front lead</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reliance 4-Front lead implantation</intervention_name>
    <description>The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
    <arm_group_label>Reliance 4-Front</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and capable of providing informed consent

          -  Has an indication for implantation of a single or dual chamber ICD or CRT-D system in
             their respective geography

          -  Subjects planned to be implanted with the RELIANCE 4-FRONT Active Fixation Lead

          -  Willing and capable of participating in all testing/ visits associated with this
             clinical study at an approved clinical study center and at the intervals defined by
             this protocol

          -  Age 18 or above, or of legal age to give informed consent specific to state and
             national law

        Exclusion Criteria:

          -  Known or suspected sensitivity to Dexamethasone Acetate (DXA)

          -  Mechanical tricuspid heart valve

          -  Subject is enrolled in any other concurrent study without prior written approval from
             Boston Scientific (BSC), with the exception of local mandatory governmental registries
             and observational studies/registries that are not in conflict and do not affect the
             following:

          -  Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause
             additional or missed visits);

          -  RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart
             rate of the subject);

          -  Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International
             Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations

          -  Currently on the active heart transplant list

          -  Documented life expectancy of less than 12 months

          -  Women of childbearing potential who are or might be pregnant at the time of study
             enrollment (method of assessment upon physician discretion)

          -  Currently requiring chronic dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Grazia Bongiorni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Pisa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landesklinikum St. Poelten</name>
      <address>
        <city>St. Pölten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospitals</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Cardiovasculaire - Paris Sud</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78306</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Alessandro Manzoni</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <zip>2790-134</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29019</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <results_first_submitted>April 12, 2017</results_first_submitted>
  <results_first_submitted_qc>April 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reliance</keyword>
  <keyword>Implantable Cardioverter Defibrillator (ICD)</keyword>
  <keyword>Cardiac Resynchronization Therapy - Defibrillator (CRT-D)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>167 patients were enrolled in the study. Patients were considered enrolled when the consent form was signed regardless whether they received the RELIANCE 4FRONT lead or not. Recruitment started on 22 November 2012. Last patient was enrolled 9 March 2014.</recruitment_details>
      <pre_assignment_details>No wash out or run-in period was planned for the study. 3 patients did not receive the study lead: lead not available at site, wrong lead chosen and patient needed MRI (magnet resonance imaging) compatible lead, while the RELIANCE 4FRONT lead was not labeled MRI compatible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Reliance 4-Front</title>
          <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study device not used</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reliance 4-Front</title>
          <description>Single arm, all patients will be implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation should be from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.26" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complication Free Rate</title>
        <description>Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.</description>
        <time_frame>3-months follow-up</time_frame>
        <population>Patients enrolled in the study and having received the RELIANCE 4FRONT active fixation lead</population>
        <group_list>
          <group group_id="O1">
            <title>Reliance 4-Front</title>
            <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
          </group>
        </group_list>
        <measure>
          <title>Complication Free Rate</title>
          <description>Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.</description>
          <population>Patients enrolled in the study and having received the RELIANCE 4FRONT active fixation lead</population>
          <units>percentage of all subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="92.9" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complication Free Rate</title>
        <description>Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant.</description>
        <time_frame>3 months through 15 months post implant</time_frame>
        <population>156 patients remained after 3 months in the study without lead related complication. Those were used for the secondary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Reliance 4-Front</title>
            <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
          </group>
        </group_list>
        <measure>
          <title>Complication Free Rate</title>
          <description>Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant.</description>
          <population>156 patients remained after 3 months in the study without lead related complication. Those were used for the secondary endpoint.</population>
          <units>percentage of total participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Complication Free Rate</title>
        <description>Lead-related Complication-Free Rate from 3 Months through 24 Months Post-Implant</description>
        <time_frame>3 Months through 24 Months Post-Implant</time_frame>
        <population>Patients remaining after the 3 months follow-up in the study until the 24 months follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Reliance 4-Front</title>
            <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
          </group>
        </group_list>
        <measure>
          <title>Complication Free Rate</title>
          <description>Lead-related Complication-Free Rate from 3 Months through 24 Months Post-Implant</description>
          <population>Patients remaining after the 3 months follow-up in the study until the 24 months follow-up.</population>
          <units>percentage of all participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pacing Threshold</title>
        <description>Pacing Threshold at 0.5 ms pulse width at 3 Months Post-Implant</description>
        <time_frame>3-months post-implant</time_frame>
        <population>Patients having undergone the 3 months follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Reliance 4-Front</title>
            <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
          </group>
        </group_list>
        <measure>
          <title>Pacing Threshold</title>
          <description>Pacing Threshold at 0.5 ms pulse width at 3 Months Post-Implant</description>
          <population>Patients having undergone the 3 months follow-up visit.</population>
          <units>Volt</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.48" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sensed Amplitude</title>
        <description>Sensed Amplitude at 3 Months Post-Implant</description>
        <time_frame>3 Months Post-Implant</time_frame>
        <population>Patients having undergone the 3 months follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Reliance 4-Front</title>
            <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensed Amplitude</title>
          <description>Sensed Amplitude at 3 Months Post-Implant</description>
          <population>Patients having undergone the 3 months follow-up</population>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="17.1" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pacing Impedance</title>
        <description>Pacing Impedance at 3 Months Post-Implant</description>
        <time_frame>3 Months Post-Implant</time_frame>
        <population>Patients with 3 month follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Reliance 4-Front</title>
            <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
          </group>
        </group_list>
        <measure>
          <title>Pacing Impedance</title>
          <description>Pacing Impedance at 3 Months Post-Implant</description>
          <population>Patients with 3 month follow-up</population>
          <units>Ohm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474" lower_limit="457" upper_limit="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from enrollment through 24 months.</time_frame>
      <desc>Definitions do not differ from clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Reliance 4-Front</title>
          <description>Single arm, all patients were implanted with the Reliance 4-Front lead
Reliance 4-Front lead implantation: The patients selected for participation were from the investigator’s general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>BSC internal coding</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal laboratory values</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate tachy therapy - SVT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity (PEA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYARRHYTHMIAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation (VF)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (VT)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Torsades des pointes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation (AF)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions (PVC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Syncope - Heart failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest pain - Heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Peripheral edema - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary edema - Heart failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fatigue - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dehydration - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Multi-system failure - Heart failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest pain - Ischemic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction - General</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Unable to capture - RV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Elevated threshold - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 ohms - RV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dislodgment - Multiple signs - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Other - Lead - Procedure: implant failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Multiple symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Head, eyes, ears, nose, throat (HEENT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Multi-system failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (&gt; 30 days post-implant)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&lt;=30 days post-implant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological effect due to device therapy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Post-surgical pocket hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary venous dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>BSC internal coding</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Unable to capture - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (VT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nonsustained ventricular tachycardia (NSVT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYARRHYTHMIAS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation (AF)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Other SVT (AVRT, AVNRT, EAT etc.)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Peripheral edema - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction - General</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dislodgment - Multiple signs - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Unable to capture - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - LV</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Other - Lead - Procedure: difficulties due to venous access</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>wound infection after LV lead placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Localized infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Head, eyes, ears, nose, throat (HEENT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hematoma - Pocket (&lt;=30 days post-implant)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Other-PG system-Procedure: Other non system related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction - Respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Post-surgical infection (&lt;= 30 days post-implant)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size was rather small and power of the study is only 80%.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ursula Appl</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>003224167213</phone>
      <email>ursula.appl@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

